The Technical Analyst
Renalytix AI plc [RNLX]
Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
Renalytix AI plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
1.16% $0.708
America/New_York / 24 apr 2024 @ 09:39
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 44.68 mill |
| EPS: | -0.900 |
| P/E: | -0.790 |
| Earnings Date: | Jun 11, 2024 |
| SharesOutstanding: | 63.11 mill |
| Avg Daily Volume: | 1.906 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.790 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.790 | industry: PE -4.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.559 - 0.841 ( +/- 20.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-20 | Coste Catherine | Buy | 95 000 | Employee Stock Option (right to buy) |
| 2023-11-20 | Levangie Daniel J | Buy | 95 000 | Employee Stock Option (right to buy) |
| 2023-11-20 | Parikh Chirag R. | Buy | 95 000 | Employee Stock Option (right to buy) |
| 2023-11-20 | Mills Christopher | Buy | 95 000 | Employee Stock Option (right to buy) |
| 2023-11-20 | Doran Howard Jr | Buy | 300 000 | Employee Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 37.34 |
| Last 26 transactions |
| Buy: 3 353 296 | Sell: 1 641 743 |
Forecast:
11:18 - $0.695
Live Trading Signals (every 1 min)
Forecast
1: 09:48 - $0.706
Forecast 2: 10:38 - $0.697
Forecast 3: 11:18 - $0.695
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.708 (1.16% ) |
| Volume | 0.0117 mill |
| Avg. Vol. | 1.906 mill |
| % of Avg. Vol | 0.615 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RNLX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 13 - 10:20 | buy | $1.070 | N/A | Active |
|---|
RNLX
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Latest Press Releases
2024-04-08 07:00:00 - Press Release
Renalytix Announces Financing With Expected Size Of Up To $4 Million
London and salt lake city, april 08, 2024 (globe newswire) -- renalytix plc (nasdaq: rnlx) (lse: renx) announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per nasdaq ads ($0.375 per common stock share) (£0.0025 each) (the “ordinary shares”) (the “fundraise”) to db capital partners healthcare, l.p. (the “purchaser”), a specialty healthcare institutional investor focused on innovative medical technology that fundamentally changes critical global diseases care. the fundraise was conducted by way of a securities purchase agreement between the purchaser and the company which consists of an initial tranche of 2,666,667 ordinary shares initially for an amount of $1...
2024-03-14 07:00:00 - Press Release
Kidneyintelx™ Included In Final Kdigo 2024 Clinical Guideline For Chronic Kidney Disease (ckd)
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk guidelines highlight the importance of risk prediction and personalized treatment to reduce risk
2024-02-15 07:00:00 - Press Release
Renalytix Reports Financial Results For Second Quarter Of Fiscal Year 2024
London and salt lake city, feb. 15, 2024 (globe newswire) -- renalytix plc (nasdaq: rnlx) (lse: renx) (the “company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, today reported financial results for the fiscal second quarter ended december 31, 2023. the company plans to issue another announcement following today's report of financial results regarding the date and time of its conference call and webcast to discuss second quarter financial results and other key events.
2024-02-09 09:00:00 - Press Release
Renalytix To Participate In The Btig Medtech, Digital Health, Life Science & Diagnostic Tools Conference
London and salt lake city, feb. 09, 2024 (globe newswire) -- renalytix plc (nasdaq: rnlx) (lse: renx) (the “company”) today announced that the company will be participating in the upcoming btig medtech, digital health, life science & diagnostic tools conference, which will take place february 13-14, 2024 in snowbird, utah. given the format of this event, no formal company presentation is expected. management will be participating in one-on-one meetings with investors during the event and meetings can be requested through btig.
2024-01-10 07:00:00 - Press Release
New Published Data Demonstrates Kidneyintelx™ Has Broad Implications For Winning War On Chronic Kidney Disease
Electronic health record deployment of kidneyintelx was associated with clinical actions that slowed progression of chronic kidney disease and improved type 2 diabetes control in just 12 months
Latest News
2024-03-25 15:58:28 - InvestorPlace
3 Ridiculously Enticing Stocks to Buy for Under a Buck
Let's keep it real in this joint – you should generally avoid stocks under $1. Yes, they're “cheap” but that's not necessarily a good thing.
2024-02-15 06:38:48 - Proactive Investors
Renalytix slides by a third as funding moves front and centre
Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile. Losses are inevitable for an early-stage company such as Renalytix, which is developing diagnostics tools for kidney illness sufferers, but the scale seemingly is raising some alarms.
2024-02-09 05:44:53 - Proactive Investors
Renalytix rises on draft Medicare determination
Shares in Renalytix PLC (AIM:RENX) jumped almost 30% on Friday after the diagnostics firm revealed a draft Medicare determination for its kidney function tests. The Centers for Medicare and Medicaid Services published the draft local coverage determination on Thursday, Renalytix said, relating to the use of its tests for those on the US state-funded medical insurance programme.
2023-10-26 07:31:35 - Zacks Investment Research
New Strong Buy Stocks for October 26th
GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.
2023-10-16 13:32:46 - Zacks Investment Research
What Makes Renalytix AI PLC Sponsored ADR (RNLX) a New Strong Buy Stock
Renalytix AI PLC Sponsored ADR (RNLX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-10-12 09:01:32 - Zacks Investment Research
New Strong Buy Stocks for October 12th
BTE, AZEK, SOLO, RNLX and RSKD have been added to the Zacks Rank #1 (Strong Buy) List on October 12, 2023.
2023-10-06 04:26:01 - Proactive Investors
Renalytix sinks to near year low despite news of strengthening US patents
Renalytix PLC (AIM:RENX) shares fell 12% to 46.09p after it said newly allowed US patents further strengthen the core intellectual property underpinning its KidneyIntelX blood test technology. The US Patent Office issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test.
2023-10-05 11:17:31 - Zacks Investment Research
Renalytix AI PLC Sponsored ADR (RNLX) Loses -44.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Renalytix AI PLC Sponsored ADR (RNLX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-10-03 04:09:53 - Proactive Investors
Renalytix surges 28% Medicaid news
Shares of Renalytix PLC (AIM:RENX) surged 28% in early trading after the Centers for Medicare & Medicaid Services (CMS) announced a price of $950 for the company's FDA-approved kidneyintelX.dkd test. The test, which uses artificial intelligence to predict risks for people with type 2 diabetes and chronic kidney disease, will be listed on the nationwide Clinical Laboratory Fee Schedule starting January 1, and the price will be locked in for at least three years.
2023-09-29 20:43:05 - Seeking Alpha
Renalytix Plc (RNLX) Q4 2023 Earnings Call Transcript
Renalytix Plc (NASDAQ:RNLX ) Q4 2023 Earnings Conference Call September 28, 2023 8:30 AM ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Thomas McLain - President James Sterling - Chief Financial Officer Conference Call Participants Christopher Glasper - Singer Capital Markets Mark Massaro - BTIG Jens Lindqvist - Investec Yi Chen - H.C. Wainwright Operator Good morning, and welcome to the Renalytix Conference Call to Review Fourth Quarter and Full-Year Fiscal 2023 Financial Results.